Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
NCT04167761Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ertugliflozin in cardiovascular disease (CVD), atherosclerosis, type 2 diabetes mellitus (T2DM) and 1 more, sponsored by Stanford University. Primary endpoint: Rate of Isoproterenol-Stimulated Lipolysis in Adipose Tissue Depots to Measure Metabolic Flexibility up to 15 minutes. Started Jul 2020; status: completed.
02
Drugs
ertugliflozin
03
Conditions
cardiovascular disease (CVD)atherosclerosistype 2 diabetes mellitus (T2DM)insulin resistance (IR)
Beyond the preview
Go deeper on NCT04167761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167761.